Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]APN-1607 PET in PSP
NCT05005819Phase 1Completed
- Sponsor
- Invicro
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florzolotau in progressive supranuclear palsy (PSP), sponsored by Invicro. Primary endpoint: Change in standardized uptake value ratios (SUVRs) of regional [18F]APN-1607 at 72 weeks. Started May 2021; status: completed.
02
Drugs
florzolotau
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT05005819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005819.